NDA Accepted for Bio-T-Gel for Male Hypogonadism
BioSante Pharmaceuticals announced that its NDA for the treatment of male hypogonadism has been accepted by the FDA following submission in January 2011 by a subsidiary of Teva Pharmaceuticals. The FDA's PDUFA date is set for November 14, 2011.
Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels.
For more information call (847) 478-0500 or visit www.biosantepharma.com.